India’s Sun Pharma Reported Bid For Bausch & Lomb And Meda Raises Hopes For Bigger Buyouts
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma has been increasingly linked to a potential global deal in the branded and specialty segments. With former Teva CEO Israel Makov as Sun’s chairman, and robust earnings continuing to pour in, a deal may be just around the corner.
You may also be interested in...
Eye On The Prize: For $8.7 Billion, Valeant Will Acquire Bausch & Lomb
As with its Medicis buyout in 2012, Valeant is acquiring another company to serve essentially as a therapeutic division within the specialty pharma the Canadian firm is cobbling together from relentless M&A activity. Buying B&L will increase Valeant’s eye care holdings substantially.
Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma
MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.